title: The route of immunization with adenoviral vaccine influences the recruitment of cytotoxic T lymphocytes in the lung that provide potent protection from influenza A virus.
abstract: Virus-specific cytotoxic T lymphocytes (CTLs) in the lung are considered to confer protection from respiratory viruses. Several groups demonstrated that the route of priming was likely to have an implication for the trafficking of antigen-specific CTLs. Therefore, we investigated whether the route of immunization with adenoviral vaccine influenced the recruitment of virus-specific CTLs in the lung that should provide potent protection from influenza A virus. Mice were immunized with recombinant adenovirus expressing the matrix (M1) protein of influenza A virus via various immunization routes involving intraperitoneal, intranasal, intramuscular, or intravenous administration as well as subcutaneous administration in the hind hock. We found that the immunization route dramatically impacted the recruitment of M1-specific IFN-γ(+) CD8(+) T cells both in the lung and the spleen. Surprisingly, hock immunization was most effective for the accumulation in the lung of IFN-γ-producing CD8(+) T cells that possessed M1-specific cytolytic activity. Further, antigen-driven IFN-γ(+) CD8(+) T cells in the lung, but not in the spleen, were likely to be correlated with the resistance to challenge with influenza A virus. These results may improve our ability to design vaccines that target virus-specific CTL responses to respiratory viruses such as influenza A virus.
authors: Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho, Iruma-gun, Saitama 350-0495, Japan.
authors: Tatsuya
authors: T
authors: Suda
authors: Masaaki
authors: M
authors: Kawano
authors: Yasuhisa
authors: Y
authors: Nogi
authors: Naohito
authors: N
authors: Ohno
authors: Toshitaka
authors: T
authors: Akatsuka
authors: Masanori
authors: M
authors: Matsui
mesh_terms: D000256:Adenoviridae / Q000737:chemistry / Q000276:immunology; D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000166:cytology / Q000276:immunology* / Q000821:virology; D002465:Cell Movement / Q000187:drug effects; D004333:Drug Administration Routes; D005260:Female; D005434:Flow Cytometry; D005822:Genetic Vectors / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology; D006801:Humans; D009980:Influenza A virus / Q000187:drug effects* / Q000276:immunology; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000276:immunology; D007279:Injections, Subcutaneous; D007371:Interferon-gamma / Q000032:analysis / Q000096:biosynthesis; D008168:Lung / Q000166:cytology / Q000276:immunology* / Q000821:virology; D051379:Mice; D008810:Mice, Inbred C57BL; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D013154:Spleen / Q000166:cytology / Q000276:immunology / Q000821:virology; D014611:Vaccination / Q000379:methods*; D014614:Vaccines, Synthetic / Q000008:administration & dosage* / Q000737:chemistry / Q000276:immunology; D014763:Viral Matrix Proteins / Q000008:administration & dosage* / Q000138:chemical synthesis / Q000276:immunology
chemical_list: D007252:Influenza Vaccines; C488936:M1 protein, Influenza A virus; D014614:Vaccines, Synthetic; D014763:Viral Matrix Proteins; D007371:Interferon-gamma